Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial.
BRCA
PD-L1
TILs
homologous recombination deficiency
neoadjuvant
olaparib (Lynparza™)
triple negative breast cancer
window of opportunity clinical trial
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
27
03
2021
accepted:
11
06
2021
entrez:
15
7
2021
pubmed:
16
7
2021
medline:
16
7
2021
Statut:
epublish
Résumé
Olaparib is effective in metastatic triple negative breast cancer (TNBC) carrying germline mutations in DNA damage repair (DDR) genes Patients received olaparib for 3 weeks (3w) before standard neoadjuvant chemotherapy and underwent multiple FDG 27 patients with g Early-stage TNBC might be a target population for olaparib, irrespective of g
Identifiants
pubmed: 34262869
doi: 10.3389/fonc.2021.686776
pmc: PMC8273330
doi:
Types de publication
Journal Article
Langues
eng
Pagination
686776Informations de copyright
Copyright © 2021 Schettini, Corona, Giudici, Strina, Sirico, Bernocchi, Milani, Ziglioli, Aguggini, Azzini, Barbieri, Cervoni, Cappelletti, Molteni, Lazzari, Ferrero, Ungari, Marasco, Bruson, Xumerle, Zago, Cerra, Loddo, Williams, Paris, Scambia and Generali.
Déclaration de conflit d'intérêts
EM, AB, LX, EZ and DC were employed by Personal Genomics Ltd. GW and ML are employed at Oncologica UK Ltd., which has received project funding from AstraZeneca outside of the submitted work. DG has declared consulting fees from Novartis, Lilly and Pfizer, research funding from LILT, Novartis, Astra-Zeneca and University of Trieste outside of the submitted work. IP has declared consulting fees from Roche, Novartis, Lilly, Pfizer, Astra-Zeneca, Pierre Fabre and Ipsen outside of the submitted work. GS has declared Grant/Research Support from MSD Italia S.r.l., consulting role for TESARO Bio Italy S.r.l. Johnson & Johnson and Clovis Oncology Italy S.r.l., outside of the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Clin Oncol. 2018 Jul 10;36(20):2105-2122
pubmed: 29846122
Future Oncol. 2016 Oct;12(19):2189-93
pubmed: 27324108
Mol Cancer Ther. 2017 Dec;16(12):2892-2901
pubmed: 28958991
PLoS One. 2017 Nov 2;12(11):e0187312
pubmed: 29095867
Eur J Cancer. 2021 May;149:134-152
pubmed: 33862496
Sci Transl Med. 2016 Oct 26;8(362):362ps17
pubmed: 27797957
Ann Oncol. 2020 Dec;31(12):1623-1649
pubmed: 32979513
Radiology. 2016 Aug;280(2):576-84
pubmed: 26909647
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
Ann Oncol. 2019 Mar 1;30(3):405-411
pubmed: 30475947
Gynecol Oncol Res Pract. 2017 Feb 22;4:4
pubmed: 28250960
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Cancer Lett. 2012 Jun 28;319(2):125-129
pubmed: 22266095
Nat Cell Biol. 2006 Dec;8(12):1398-406
pubmed: 17072303
Ann Oncol. 2018 Jul 1;29(7):1497-1508
pubmed: 29873695
J Pathol. 2020 Apr;250(5):667-684
pubmed: 32129476
Front Oncol. 2020 Apr 28;10:570
pubmed: 32457830
Cell. 2016 Sep 22;167(1):260-274.e22
pubmed: 27641504
Clin Cancer Res. 2017 Jul 15;23(14):3711-3720
pubmed: 28167507
Cancer Res. 2012 Nov 1;72(21):5588-99
pubmed: 23118055
Eur J Cancer. 2020 Mar;127:240-250
pubmed: 31956037
Lancet Oncol. 2019 May;20(5):636-648
pubmed: 30948273
Cancers (Basel). 2020 Feb 08;12(2):
pubmed: 32046278
Lancet. 2020 Dec 5;396(10265):1817-1828
pubmed: 33278935
J Clin Oncol. 2011 Jun 10;29(17):2342-9
pubmed: 21555689
Clin Cancer Res. 2017 Nov 1;23(21):6468-6477
pubmed: 29093017
Semin Cancer Biol. 2018 Oct;52(Pt 2):16-25
pubmed: 29024776
Breast Dis. 2010;32(1-2):25-33
pubmed: 21778580
Cell. 2002 Jan 25;108(2):171-82
pubmed: 11832208
J Natl Cancer Inst. 2017 Aug 1;109(8):
pubmed: 28423402
Breast Cancer Res Treat. 2012 Sep;135(2):505-17
pubmed: 22875744
J Clin Oncol. 2020 Apr 20;38(12):1346-1366
pubmed: 31928404
Hum Mutat. 2008 Nov;29(11):1282-91
pubmed: 18951446
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
J Natl Cancer Inst. 2011 Nov 16;103(22):1656-64
pubmed: 21960707
Ann Oncol. 2021 Feb;32(2):240-249
pubmed: 33242536
Lancet Oncol. 2011 Sep;12(9):852-61
pubmed: 21862407
Ann Oncol. 2019 Mar 1;30(3):397-404
pubmed: 30475950
Lancet Oncol. 2020 Jan;21(1):33-43
pubmed: 31838010
J Natl Cancer Inst. 2007 Jan 17;99(2):167-70
pubmed: 17228000
Br J Cancer. 2018 Apr;118(7):933-935
pubmed: 29531322
Clin Cancer Res. 2013 Aug 15;19(16):4521-31
pubmed: 23812670
Environ Health Perspect. 1997 Jun;105 Suppl 4:775-80
pubmed: 9255561
PLoS One. 2013 Jun 25;8(6):e66243
pubmed: 23825533
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Lancet Oncol. 2020 Nov;21(11):1399-1401
pubmed: 33098760
Genet Test Mol Biomarkers. 2019 Jun;23(6):393-400
pubmed: 31063404
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
Breast Cancer Res Treat. 2001 Sep;69(2):143-51
pubmed: 11759820